|Table of Contents|

Effect of PI3K inhibitor ZSTK-474 on proliferation and invasion of colorectal cancer cells

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2020 04
Page:
548-552
Research Field:
Publishing date:

Info

Title:
Effect of PI3K inhibitor ZSTK-474 on proliferation and invasion of colorectal cancer cells
Author(s):
Li Dong; Zhu Changli; Wan Yufeng
The Affiliated Huai'an Hospital of Xuzhou Medical University,the Second People's Hospital of Huai'an，Jiangsu Huai'an 223002，China.
Keywords:
colorectal cancer; cell proliferation; cell invasion; ZSTK-474
PACS:
R735
DOI:
10.3969/j.issn.1672-4992.2020.04.006
Abstract:
Objective：Toinvestigate the effect of ZSTK-474 on proliferation and invasion of colorectal cancer cells.Methods：HT-29 and HCT-116 cells were treated with different concentrations(0，1，2，4，6，8 and 10 μmol/L) of ZSTK-474 for 24 h and 48 h.CCK8 assay was used to determine the cell viability,and the half ihhibitory concentration (IC50) was calculated.HT-29 and HCT-116 cells treated with 4 μmol/L ZSTK-474 were used as the experimental group according to the value of IC50,and those treated with 0.1% DMSO as the control group.The cell proliferation was detected by Colony-forming assay.Cell apoptosis was examined by flow cytometry,and cell invasion was evaluated by Transwell assay.The mRNA expression of PI3K and Akt were determined by qRT-PCR,and the protein expression of PI3K and Akt were assessed by Western blot.Results：ZSTK-474 significantly inhibited the proliferation and invasion of HT-29 and HCT-116 cells in a time and dose dependent manner.ZSTK-474 did not affect the apoptosis of HT-29 and HCT-116 cells.The mRNA and protein expression of PI3K and Akt were inhibited in HT-29 and HCT-116 cells with ZSTK-474 treated for 24 h.Conclusion：ZSTK-474 inhibits colorectal cancer cells proliferation and invasion in vitro．

References:

［1］ Siegel RL,Miller KD,Jemal A.Cancer Statistics,2017［J］.CA Cancer J Clin,2017,67(1):7-30.
［2］ Arnold M,Sierra MS,Laversanne M,et al.Global patterns and trends in colorectal cancer incidence and mortality［J］.Gut,2017,66(4):683-691.
［3］ Dai Z,Zheng RS,Zou XN,et al.Analysis and prediction of colorectal cancer incidence trend in China［J］.Chinese Journal of Preventive Medicine,2012,46(7):598-603.
［4］ Chen W,Zheng R,Baade PD,et al.Cancer statistics in China,2015［J］.CA Cancer J Clin,2016,66(2):115-132.
［5］ Liu S,Zheng R,Zhang M,et al.Incidence and mortality of colorectal cancer in China,2011［J］.Chin J Cancer Res,2015,27(1):22-28.
［6］ Pompura SL,Dominguez-Villar M.The PI3K/AKT signaling pathway in regulatory T-cell development,stability,and function［J］.J Leukoc Biol,2018,103(6):1065-1076.
［7］ Lonetti A,Cappellini A,Bertaina A,et al.Improving nelarabine efficacy in T cell acute lymphoblastic leukemia by targeting aberrant PI3K/AKT/mTOR signaling pathway［J］.J Hematol Oncol,2016,9(1):114.
［8］ Li N,Bu X,Tian X,et al.Fatty acid synthase regulates proliferation and migration of colorectal cancer cells viaHER2-PI3K/Akt signaling pathway［J］.Nutr Cancer,2012,64(6):864-870.
［9］ Jia Y,Xiao Z,Gongsun X,et al.CEP55 promotes the proliferation,migration and invasion of esophageal squamous cell carcinoma via the PI3K/Akt pathway［J］.Onco Targets Ther,2018（11）:4221-4232.
［10］ Tang Y,Pan J,Huang S,et al.Downregulation of miR-133a-3p promotes prostate cancer bone metastasis via activating PI3K/AKT signaling［J］.J Exp Clin Cancer Res,2018,37(1):160.
［11］ Liu Z,Zhu G,Getzenberg RH,et al.The upregulation of PI3K/Akt and MAP kinase pathways is associated with resistance of microtubule-targeting drugs in prostate cancer［J］.J Cell Biochem,2015,116(7):1341-1349.
［12］ Ghigo A,Morello F,Perino A,et al.Phosphoinositide 3-kinases in health and disease［J］.Subcell Biochem,2012（58）:183-213.
［13］ Dituri F,Mazzocca A,Giannelli G,et al.PI3K functions in cancer progression,anticancer immunity and immune evasion by tumors［J］.Clin Dev Immunol,2011:947858.
［14］ Zhang Y,Wang S,Qian W,et al.338 targets p21 and cyclin D1 via PI3K/AKT pathway activationto promote cell proliferation in colorectal cancer［J］.Oncol Rep,2018,40(2):1119-1128.
［15］ Zhang H,Wang Q,Liu J,et al.Inhibition of the PI3K/Akt signaling pathway reverses sorafenib-derived chemo-resistance in hepatocellular carcinoma［J］.Oncol Lett,2018,15(6):9377-9384.
［16］ Ding X,Xi W,Ji J,et al.HGF derived from cancer-associated fibroblasts promotes vascularization in gastric cancer via PI3K/AKT and ERK1/2 signaling［J］.Oncol Rep,2018,40(2):1185-1195.
［17］ GUO YH,ZHANG W,HUANG YQ,et al.Effects of AKT inhibitor MK-2206 on proliferation and apoptosis of ovarian cancer SKOV3 cells［J］.Journal of Clinical and Experimental Medicine,2017,16(12):1181-1184.［郭红艳,张微,黄玉琴,等.AKT抑制剂MK-2206对卵巢癌SKOV3细胞增殖凋亡的影响［J］.临床和实验医学杂志,2017,16(12):1181-1184.］
［18］ Carpentier S,N' Kuli F,Grieco G,et al.Class III phosphoinositide 3-kinase/VPS34 and dynamin are critical for apical endocytic recycling［J］.Traffic,2013,14(8):933-948.
［19］ Kong DX,Yamori T.ZSTK474,a novel phosphatidylinositol 3-kinase inhibitor identified using the JFCR39 drug discovery system［J］.Acta Pharmacol Sin,2010,31(9):1189-1197.
［20］ Yaguchi S,Fukui Y,Koshimizu I,et al.Antitumor activity of ZSTK474,a new phosphatidylinositol 3-kinase inhibitor［J］.J Natl Cancer Inst,2006,98(8):545-556.
［21］ Kong D,Okamura M,Yoshimi H,et al.Antiangiogenic effect of ZSTK474,a novel phosphatidylinositol 3-kinase inhibitor［J］.Eur J Cancer,2009,45(5):857-865.
［22］ Anzai K,Sekine-Suzuki E,Ueno M,et al.Effectiveness of combined treatment using X-rays and a phosphoinositide 3-kinase inhibitor,ZSTK474,on proliferation of HeLa cells in vitro and in vivo［J］.Cancer Sci,2011,102(6):1176-1180.
［23］ Liu XL,Zhang XT,Meng J,et al.ING5 knockdown enhances migration and invasion of lung cancer cells byinducing EMT via EGFR/PI3K/Akt and IL-6/STAT3 signaling pathways［J］.Oncotarget,2017,8(33):54265-54276.
［24］ Wang Y,Liu J,Qiu Y,et al.ZSTK474,a specific class I phosphatidylinositol 3-kinase inhibitor,induces G1 arrest and autophagy in human breast cancer MCF-7 cells［J］.Oncotarget,2016,7(15):19897-19909.
［25］ Barollo S,Bertazza L,Baldini E,et al.The combination of RAF265,SB590885,ZSTK474 on thyroid cancer cell lines deeply impact on proliferation and MAPK and PI3K/Akt signaling pathways［J］.Invest New Drugs,2014,32(4):626-635.
［26］ Lin L,Gaut D,Hu K,et al.Dual targeting of glioblastoma multiforme with a proteasome inhibitor (Velcade) and a phosphatidylinositol 3-kinase inhibitor (ZSTK474)［J］.Int J Oncol,2014,44(2):557-562.
［27］ Bi QJ,Men XJ,Han R,et al.LHX6 inhibits the proliferation,invasion and migration of breast cancer cells by modulating the PI3K/Akt/mTOR signaling pathway［J］.Eur Rev Med Pharmacol Sci,2018,22(10):3067-3073.
［28］ Amin H,Wani NA,Farooq S,et al.Inhibition of invasion in pancreatic cancer cells by conjugate of EPA with β(3,3)-Pip-OH via PI3K/Akt/NF-kB pathway［J］.ACS Med Chem Lett,2015,6(10):1071-1074.

Memo

Memo:
-
Last Update: 2020-01-14